Elypta interim study LEVANTIS-0087A results show glycosaminoglycan's potential to predict the risk of developing any cancer with a simple urine test
The results will be presented at the 2024 American Association for Cancer Research Annual Meeting Stockholm, April 8, 2024: Swedish early cancer detection company Elypta announces that the interim results from the LEVANTIS-0087A study will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego during the Biomarker-Based Screening session on April 9 (1:30 - 5:00 PM PT).The population-based case-control study included 2,054 adults over the age of 18 with no symptoms of cancer from the Lifelines Cohort Study in the Netherlands. The results